Trends in effectiveness of inactivated influenza vaccine in children by age groups in seven seasons immediately before the COVID-19 era

Shinjoh, Masayoshi; Furuichi, Munehiro; Kobayashi, Hisato; Yamaguchi, Yoshio; Maeda, Naonori; Yaginuma, Mizuki; Kobayashi, K.; Nogayama, Taisuke; Chiga, Michiko; Oshima, Mio; Kuramochi, Yuu; Yamada, Go; Narabayashi, Atsushi; Ookawara, Ichiro; Nishida, Mitsuhiro; Tsunematsu, Kenichiro; Kamimaki, Isamu; Shimoyamada, Motoko; Yoshida, Makoto; Shibata, Akimichi; Nakata, Yuji; Taguchi, Nobuyuki; Mitamura, Keiko; Takahashi, Tsuyoshi

doi:10.1016/j.vaccine.2022.04.033

Vaccine

2022

DOI: 10.1016/j.vaccine.2022.04.033

|View full text |Cite

Trends in effectiveness of inactivated influenza vaccine in children by age groups in seven seasons immediately before the COVID-19 era

Masayoshi Shinjoh

Munehiro Furuichi

Hisato Kobayashi

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2022

2024

Publication Types

Select...

Article4

Relationship

Self Cite0

Independent4

Authors

Journals

Cited by 4 publications

(2 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In Japan, rapid antigen detection tests (RADTs) for influenza and RSV are routinely performed in pediatric clinical settings. 9,10 Human rhinovirus (HRV) is the most frequent viral pathogen of the common cold, although a variety of respiratory viruses are the causes. 11 HRV was predominant and relatively unaffected during the coronavirus disease 2019 (COVID-19) pandemic despite nonpharmaceutical interventions.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Human Rhinovirus as a Cause of Fever in Neonates and Young Infants During the COVID-19 Pandemic, 2020–2022

Aizawa,

Ikuse,

Izumita

et al. 2023

Pediatric Infectious Disease Journal

View full text Add to dashboard Cite

Background: Human rhinovirus (HRV) was predominant and persistent during the coronavirus disease 2019 (COVID-19) pandemic despite nonpharmaceutical interventions. The data whether HRV persistence also occurred in neonates and young infants were very limited. Methods: This prospective observational study was conducted in Niigata, Japan, between January 2020 and September 2022. The participants were hospitalized neonates and infants aged less than 4 months with fever. We excluded patients with evidence of bacterial infection or obvious sick contact with influenza or respiratory syncytial virus infection, as confirmed by rapid antigen detection tests. COVID-19 diagnosed by polymerase chain reaction (PCR) or rapid antigen detection tests were also excluded. Parechovirus and enterovirus were examined by PCR using serum and/or cerebrospinal fluid. FilmArray Respiratory Panel v1.7 was conducted on nasopharyngeal swabs. If HRV was positive, the genotype was identified. Results: We included 72 patients (median age, 54 days; interquartile range, 28.5–79 days), and sepsis was diagnosed in 31 (43.1%) patients. In total, 27 (37.5%) patients had had positive multiplex PCR tests. These patients were more likely to have rhinorrhea (P = 0.004), cough (P = 0.01), and sick contact (P < 0.001) than those who with negative multiplex PCR. HRV was the most frequently detected virus (n = 23, 85.2%), and species A (n = 15, 71.4%) and C (n = 6, 28.6%) were genotyped. No seasonality or monthly predominance of the specific HRV types was observed. Conclusions: HRV was an important cause of fever in neonates and young infants during the COVID-19 pandemic, 2020 to 2022.

show abstract

mentioning

confidence: 99%

“…In Japan, rapid antigen detection tests (RADTs) for influenza and RSV are routinely performed in pediatric clinical settings. 9,10…”

mentioning

confidence: 99%

Human Rhinovirus as a Cause of Fever in Neonates and Young Infants During the COVID-19 Pandemic, 2020–2022

Aizawa,

Ikuse,

Izumita

et al. 2023

Pediatric Infectious Disease Journal

View full text Add to dashboard Cite

show abstract

Effectiveness of inactivated influenza and COVID-19 vaccines in hospitalized children in 2022/23 season in Japan – The first season of co-circulation of influenza and COVID-19

Shinjoh

Furuichi

Tsuzuki

et al. 2023

Vaccine

View full text Add to dashboard Cite

Effectiveness of inactivated influenza vaccine in children during the 2023/24 season: The first season after relaxation of intensive COVID-19 measures

Shinjoh,

Yaginuma,

Yamaguchi

et al. 2024

Vaccine

View full text Add to dashboard Cite

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Trends in effectiveness of inactivated influenza vaccine in children by age groups in seven seasons immediately before the COVID-19 era

Cited by 4 publications

References 44 publications

Human Rhinovirus as a Cause of Fever in Neonates and Young Infants During the COVID-19 Pandemic, 2020–2022

Human Rhinovirus as a Cause of Fever in Neonates and Young Infants During the COVID-19 Pandemic, 2020–2022

Effectiveness of inactivated influenza and COVID-19 vaccines in hospitalized children in 2022/23 season in Japan – The first season of co-circulation of influenza and COVID-19

Effectiveness of inactivated influenza vaccine in children during the 2023/24 season: The first season after relaxation of intensive COVID-19 measures

Contact Info

Product

Resources

About